Pfizer Inc. (PFE) |
| 27.32 0.4 (1.49%) 04-13 15:59 |
| Open: | 26.83 |
| High: | 27.57 |
| Low: | 26.68 |
| Volume: | 44,007,893 |
| Market Cap: | 155,349(M) |
| PE Ratio: | 20.09 |
| Exchange: | New York Stock Exchange |
| Industry: | Drug Manufacturers - General |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 28.75 |
| Resistance 1: | 27.83 |
| Pivot price: | 27.48 |
| Support 1: | 26.36 |
| Support 2: | 21.93 |
| 52w High: | 28.75 |
| 52w Low: | 21.87 |
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
| EPS | 1.360 |
| Book Value | 15.210 |
| PEG Ratio | 0.00 |
| Gross Profit | 8.337 |
| Profit Margin (%) | 12.42 |
| Operating Margin (%) | 23.94 |
| Return on Assets (ttm) | 5.7 |
| Return on Equity (ttm) | 8.9 |
Mon, 13 Apr 2026
Pfizer (PFE) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Sun, 12 Apr 2026
BofA Lowers its Price Target on Pfizer (PFE) to $26 from $27 - Yahoo Finance
Sat, 11 Apr 2026
Pfizer Inc (PFE) Stock Price Quote Today & Current Price Chart - Capital.com
Fri, 10 Apr 2026
Pfizer (NYSE: PFE) SVP discloses stock and appreciation right holdings - Stock Titan
Fri, 10 Apr 2026
Pfizer Inc. (PFE) is a trending stock: Facts to know before betting on it - MSN
Mon, 30 Mar 2026
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know - Yahoo Finance
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |